Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05809310
Other study ID # NL81160
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 18, 2023
Est. completion date September 30, 2025

Study information

Verified date May 2023
Source UMC Utrecht
Contact Hans Breur, MD, PhD
Phone +31 88 75 754 59
Email h.breur@umcutrecht.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The main question[s] it aims to answer are: The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions. Participants will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions. Researchers will compare the difference in VO2 max (% predicted) between the interventional group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo a percutaneous intervention for a PA stenosis) and the control group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo conservative management)


Description:

Rationale: Postoperative survival of patients with dextro transposition of the great arteries (d-TGA), Tetralogy of Fallot (ToF) and Truncus Arteriosus (TA) has increased over the last decades due to advances in operative techniques and perioperative care. Despite postoperative survival has increased, morbidity of these patients increases during long-term follow-up with a high need for reinterventions. Right ventricular outflow tract (RVOT) obstructions are the most common indication for a reintervention and percutaneous branch pulmonary artery (PA) interventions account for a significant number of these reinterventions. However, the effects of percutaneous branch PA interventions on exercise capacity, RV function and RV adaptation of patients with d-TGA, ToF and TA remains largely unknown. In addition, there is no consensus about the optimal timing for percutaneous interventions for branch PA stenosis in international guidelines. Objective: The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions. Study design: This is a multicenter randomized controlled trial. Patients will be included from the following Dutch interventional centers for congenital heart disease: UMC Utrecht/WKZ (sponsor), LUMC/AUMC and Erasmus MC. During this trial there will be two groups: 1. a group of patients with d-TGA, ToF and TA who will undergo a percutaneous intervention for a branch PA stenosis according to standard care (intervention group) and 2. a group of patients with d-TGA, ToF and TA with a similar degree of pulmonary stenosis as group 1 (class IIa indication) who will undergo conservative management for a branch PA stenosis according to standard care (control group). If necessary, the control group will be able to undergo a percutaneous intervention for branch PA stenosis after the examinations at approximately 6 months follow-up, or sooner in case of symptoms. Patients from both groups will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions. Study population: d-TGA post ASO, ToF or TA patients ≥8 years old will be included if they have a class IIa indication for a percutaneous intervention for branch PA stenosis according to the international guidelines. Patients will be excluded if they contraindications for one of the examinations. Main study parameters/endpoints: the difference in VO2 max (% predicted) as parameter for exercise capacity between the interventional and control group.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date September 30, 2025
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 8 Years and older
Eligibility Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Patients with d-TGA post ASO, ToF or TA - =8 years Exclusion Criteria: One or more of the following inclusion criteria: - All class IIa indications for a branch PA intervention: - Persistent decreased RV function (based on gold standard CMR) - <18 years RVEF =55% (28) - =18 years RVEF<50% (29) - Progressive tricuspid regurgitation (TR) (=moderate) - Isolated bifurcation stenosis: - Significant unilateral stenosis (=50%) - Borderline bilateral PA stenosis (40-70%) - Unbalanced perfusion (=35/65%) - RV/LV pressure ratio > 2/3 based on echocardiography - Reduced lung perfusion or decreased objective exercise capacity (based of gold standard VO2 max during CPET) - <18 years VO2 peak <35 mL·kg-1·min-1 (boys) VO2 peak <30 mL·kg-1·min-1 (girls) (30) - =18 years VO2 peak <27 mL·kg-1·min-1 (men) VO2 peak <19 mL·kg-1·min-1 (women) (31)

Study Design


Intervention

Procedure:
Percutaneous intervention (stent) for PA stenosis
Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries

Locations

Country Name City State
Netherlands Amsterdam University Medical Center location AMC Amsterdam
Netherlands Leiden University Medical Center Leiden
Netherlands Erasmus Medical Center Rotterdam
Netherlands UMC Utrecht/WKZ Utrecht

Sponsors (6)

Lead Sponsor Collaborator
UMC Utrecht Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC), Dutch Heart Foundation, Erasmus Medical Center, Hartekind, Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity using cardiopulmonary exercise test on a treadmill change between baseline and 6 months follow-up
Secondary Technical success using invasive right ventricular and pulmonary artery pressures and gradients Technical success of the intervention using invasive right ventricular and pulmonary artery pressures and gradients after the intervention, an average of 1 month after baseline
Secondary Peak workload (W) using cardiopulmonary exercise test on a treadmill at baseline, 6 months follow-up and 2-4 years follow-up
Secondary Peak workload (% predicted) using cardiopulmonary exercise test on a treadmill at baseline, 6 months follow-up and 2-4 years follow-up
Secondary O2 pulse (ml) using cardiopulmonary exercise test on a treadmill at baseline, 6 months follow-up and 2-4 years follow-up
Secondary O2 pulse (% predicted) using cardiopulmonary exercise test on a treadmill at baseline, 6 months follow-up and 2-4 years follow-up
Secondary VE/VCO2 slope using cardiopulmonary exercise test on a treadmill at baseline, 6 months follow-up and 2-4 years follow-up
Secondary Right ventricular ejection fraction (%) using CMR at baseline, 6 months follow-up and 2-4 years follow-up
Secondary RV strain (%) using speckle tracking echocardiography and CMR feature tracking at baseline, 6 months follow-up and 2-4 years follow-up
Secondary RV fractional area change (%) using echocardiography at baseline, 6 months follow-up and 2-4 years follow-up
Secondary RV pressure (mmHg) using echocardiography (TI gradient) at baseline, 6 months follow-up and 2-4 years follow-up
Secondary RV end-systolic elastance using pressure-volume analysis before and after the intervention, an average of 1 month after baseline
Secondary RV end systolic volume (ml and ml/m2) using CMR at baseline, 6 months follow-up and 2-4 years follow-up
Secondary RV end diastolic volume (ml and ml/m2) using CMR at baseline, 6 months follow-up and 2-4 years follow-up
Secondary RV functional reserve RVEF dobutamine - RVEF rest using a low dose dobutamine stress MRI at baseline and 6 months follow-up in the interventional group from UMC Utrecht and Erasmus MC
Secondary RV mass (g and g/m2) using CMR at baseline, 6 months follow-up and 2-4 years follow-up
Secondary Right ventricular pulmonary arterial (RV-PA) coupling using pressure-volume analysis before and after the intervention, an average of 1 month after baseline
Secondary Lung perfusion (%) using CMR at baseline, 6 months follow-up and 2-4 years follow-up
Secondary Quality of Life (QoL) in 4 domains: health and related activities, emotional, social and school/work using PedsQL questionnaire at baseline and 2 weeks follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04992793 - Paediatric Brain Injury Following Cardiac Interventions
Recruiting NCT05213598 - Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Completed NCT04136379 - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Completed NCT04814888 - 3D Airway Model for Pediatric Patients
Recruiting NCT04920643 - High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery N/A
Completed NCT05934578 - Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training N/A
Recruiting NCT06041685 - Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia N/A
Recruiting NCT05902013 - Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation N/A
Not yet recruiting NCT05687292 - Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
Not yet recruiting NCT05524324 - Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT N/A
Completed NCT02746029 - Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
Completed NCT02537392 - Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease N/A
Completed NCT03119090 - Fontan Imaging Biomarkers (FIB) Study
Recruiting NCT02258724 - Swiss National Registry of Grown up Congenital Heart Disease Patients
Completed NCT01966237 - Milrinone Pharmacokinetics and Acute Kidney Injury
Terminated NCT02046135 - Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery Phase 2
Recruiting NCT01184404 - Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery N/A
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01821287 - Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease N/A